Cargando cotizaciones...
Previsión
No hay datos de analistas disponibles para esta empresa.
Noticias Ir al feed de noticias
Basel Medical Group appoints Neo Chun How Alton as interim CFO
The Basel Medical Group has appointed Neo Chun How Alton as interim CFO with effect from Monday. He succeeds Jianing Lu, who resigned as chief financial officer. Neo brings experience in corporate finance, restructuring, forensic accounting and tax policy, and was most recently deputy CEO of InCorp Global and worked as a part-time lecturer. » Más en de.investing.com
Basel Medical Group remedies NASDAQ violation after filing amended 20-F
Basel Medical Group reports that the noncompliance with periodic reporting obligations was cured after filing the amended annual report on Form 20-F with the SEC on March 13, 2026, and that it meets NASDAQ rule 5250(c)(1). The stock rose nearly 16% last week to $0.69 but is down 83% year-to-date. The company reports more cash than debt, has a market capitalization of $12.96 million and operates clinical sites in Singapore. » Más en de.investing.com
Datos financieros de la empresa
| (EUR) | diciembre de 2025 | |
|---|---|---|
| Ingresos | 5,46 M | - |
| Beneficio bruto | -651,38 mil | - |
| Beneficio neto | 177,82 mil | - |
| EBITDA | -570,09 mil | - |
Datos fundamentales
| Métrica | Valor |
|---|---|
Capitalización bursátil | 6,66 M € |
Número de acciones | 1,57 M |
Máximo/mínimo de 52 semanas | 22,21 € - 3,59 € |
| Dividendos | No |
Beta | 0,26 |
Ratio P/E | -17,90 |
Ratio PEG | -0,18 |
Ratio P/B | 1,56 |
Ratio P/S | 0,69 |
Perfil de la empresa
| Nombre | BASEL MED GROUP LTD. O.N. |
| CEO | Yen Feng Chhoa |
| Empleados | 82 |
Descubrir activos
Los accionistas de BASEL MED GROUP LTD. O.N. también invierten en los siguientes activos
